CONDITIONS FOR RIKSBANK REVERSED AUCTIONS SEK MUNICIPAL BONDS
|Anbudsförfarande kommuner och regioner, 2021-03-09|
|Bonds||Fixed rate notes issued in SEK by Municipalities or Regions with maturity in:|
The following issuers are accepted for delivery:
Delivery may not be made in Bonds purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Specific terms, i.e. the purchase may not have been made after:
|Bids||Bids are made to tel 08-696 69 70 and confirmed in writing by a filled-in Bid form by e-mail to EOL@riksbank.se|
|Bid times||10.00-11.00 (CET/CEST) on the Bid date|
|Requested volume (corresponding nominal amount)||SEK 1000 +/- 1000 million|
|Highest permitted bid volume (corresponding nominal amount)||The total bid volume from one Counterparty for the two Credit rating classes may not exceed SEK 1 000 million.|
No bid may contain Bonds exceeding SEK 1000 million issued by Stockholms Stad, Region Stockholm (Stockholms läns landsting) or Göteborgs Stad.
For other issuers, bids may not contain Bonds exceeding SEK 100 million issued by the same issuer.
|Lowest permitted bid volume (corresponding nominal amount)||The total bid volume from one Counterparty should not be less than SEK 50 million and not be less than SEK 5 million per Bond (ISIN code).|
|Credit rating classes||The requested volume is divided into two credit rating classes. Credit rating refers to the issuer’s credit rating. If there are credit ratings from several credit rating agencies the highest of these will be applied.|
Class 1: A long-term credit rating of AAA with S&P, Aaa with Moody’s or AAA with Fitch.
Class 2: A long-term credit rating of AA+ with S&P, Aa1 with Moody’s or AA+ with Fitch.
|Maturity||Bonds maturing between January 1. 2024 and December 31. 2024. The year is divided into four quarters and bids are placed for each quarter and Credit Class.|
Example: For Credit Class 1 with maturity quarter 2, a bid of SEK 90 million is placed at interest x %.
|Expected allocation time||Not later than 11.30 (CET/CEST) on the Bid date|
|Delivery and payment date||2021-03-11|
|Delivery of bonds||Bonds issued in the PM section:|
To the Riksbank's account in Euroclear Sweden AB's securities settlement system: 1 4948 6383.
Bonds issued in the AM section:
To the Riksbank's account at the Global Custodian State Street:
Global Custodian BIC Code: SBOSUS3CXXX
Local Settlement Agent: SKANDINAVISKA ENSKILDA BANKEN AB (SEB)
Local Settlement Agent BIC Code: ESSESESSXXX
Global Custodian's Account Name at SEB: STATE STREET BANK & TRUST
Global Custodian's Account Number at SEB: 01-100 386 491
Riksbank's Account Name at the Global Custodian: SVERIGES RIKSBANK Riksbank's Account Number at the Global Custodian: 0145
PSET BIC: VPCSSESSXXX
Counterparties must use BIC: ESSESESSXXX in field 95P::DEAG/REAG and State Street BIC: SBOSUS3CXXX in field 95P::SELL/BUYR in the settlement instruction.
Bonds issued for the euro market (ISIN code with XS):
To the Riksbank's account at Euroclear Bank: 91181.
|General terms and conditions||General terms and conditions for the Riksbank´s purchases of bonds via bid procedures 2020:3. dated 20 November 2020 (see the Riksbank´s web).|
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million23.4.2021 07:00:00 CEST | Press release
GrandVision reports 1Q21 revenue of €899 million and adjusted EBITA of €79 million Schiphol, the Netherlands – 23 April 2021. GrandVision N.V. publishes its First Quarter 2021 trading update. Due to the exceptional nature of the year 2020, GrandVision will also include in the present press release comparisons versus 2019. Highlights • GrandVision continues to show resilience in the first quarter despite the most recent COVID-19 related government restrictions in Europe and Latam • At constant exchange rates, revenue declined by -0.7% compared with 1Q20 to €899 million from €926 million in 1Q20 (1Q19: €974m) • Comparable revenue declined by -1.5% versus 1Q20 and on a 2019 basis, -10.8% versus 1Q19 • Adj. EBITA increased by 98.1% at constant exchange rates to €79 million from €41 million in 1Q20 (1Q19: €107m). Continued cost discipline, structural improvements in certain territories and improved product and price mix contributed to the underlying performance • Adj. EBITA margin at 8.8%,
Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer23.4.2021 07:00:00 CEST | Press release
Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of the Executive Committee as of 1 July 2021. Mrs. Dalbiez (a French national) currently is Head of HR for the Capsules and Health Ingredients business at Lonza, based in Basel, Switzerland. Prior to that, she worked for 12 years in various HR roles at Novartis. She started her career at Deutsche Bank before working for Capital International, a global investment company. CEO Olivier Rigaud commented: "I am really pleased to welcome Aurélie to the ExCo team as a seasoned HR leader who partners closely with the business to develop talent, drive culture, engagement, continuous improvement, and customer intimacy. Her appointment will also further enhance the diversity of our ExCo." Mrs. Dalbiez brings a multi-cultural background and perspective. She lived in the United States as a child, earned her university degree in International Business in Lyon, France and worked internationally throughout
Wereldhave Trading Update Q1 202123.4.2021 07:00:00 CEST | Press release
Benelux disposal program almost completedEUR 32m new financing arranged; expected to secure liquidity until Q3 2023 soonShopping center occupancy relatively stable at 94%Successful delivery of FSC concepts in 2020 pushes NPS score to +9 from +4Outlook for 2021 direct result per share at the lower end of the previous guidance of € 1.80 - 2.00 Attachment Wereldhave Trading Update Q1 2021
Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for immunotherapy23.4.2021 07:00:00 CEST | Press release
About 90,000 women globally die from endometrial cancer each year1VENTANA MMR RxDx Panel is the first immunohistochemistry predictive test in endometrial cancer for treatment with the anti-PD1 immunotherapy JEMPERLI (dostarlimab-gxly)Roche/GSK collaboration represents an important step towards a personalised healthcare strategy that can help identify patients who are most likely to benefit from a specific therapy Basel, 23 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced U.S. Food and Drug Administration (FDA) approval of the VENTANA MMR RxDx Panel for advanced or recurrent endometrial cancer patients. MMR is a molecular mechanism that functions to correct certain errors that can spontaneously occur during DNA replication. Testing can identify patients eligible for treatment with JEMPERLI (dostarlimab-gxly) monotherapy, an anti-PD1 immunotherapy from GlaxoSmithKline (GSK) that was approved by the FDA on 22 April 2021. Endometrial cancer is the most common gynecologic can
Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies23.4.2021 06:01:00 CEST | Press release
Application is based on Phase 2b/3 SELECTION study data with patients with moderately to severely active ulcerative colitis Mechelen, Belgium;23April 2021;06.01 CET; –Galapagos NV (Euronext & Nasdaq: GLPG) today report that their collaboration partnerGilead Sciences K.K. (“Gilead”) and Eisai Co., Ltd. (“Eisai”)today announced that Gilead submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis (UC).Filgotinib is a new oral Janus kinase (JAK) inhibitor approved in Japan in September 2020 for the treatment of rheumatoid arthritis. This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study evaluating the efficacy and safety of filgotinib for the induction and maintenance of remission in patients with moderately to severely active ulcerative colitis who have had a
Camposol Holding PLC Invitation to the Presentation of Fourth Quarter and Audited Full Year 2020 Financial Results23.4.2021 02:00:00 CEST | Press release
Camposol Holding PLC will announce the results for the full year 2020 on Thursday, April 29, 2021. In connection with the release, a telephone conference will be held at 9:30 a.m. (Lima) as described below. The presentation will be published at 8:30 a.m. (Lima) and will be available on the Company's website. In connection with the earnings release Samuel Dyer Coriat, CEO, and Andrés Colichón Sas, CFO, will host a conference call presentation and a Q&A session at 9:30 a.m. (Lima). To participate in the conference call, please use the following numbers: London, UK Local +0800 028 8438 US/Canada International +1 409 981 0728 Zurich, Switzerland, Local +044 580 1740 Oslo, Norway, Local +47 8001 6162 Colombia, National Free Phone +01 800 518 5094 Chile, National Free Phone +56 800 914 686 Peru, National Free Phone +51 0800 71470 Participants will be asked for their name and conference ID. The Camposol conference ID is: 2466977 Audio access for the meeting is available by dialing the above-m
CrossAmerica Partners LP Maintains Quarterly Distribution22.4.2021 22:30:00 CEST | Press release
•Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 Allentown, PA, April 22, 2021 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250per unit attributable to the firstquarter of 2021 ALLENTOWN, PA (April 22, 2021) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2021 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 11, 2021 to all unitholders of record on May 4, 2021. CrossAmerica will host a conference call on May 11th at 9:00 a.m. Eastern Time to discuss first quarter earnings results, which will be released after the market closes on Monday, May 10. About CrossAmerica Partners LP CrossAmerica Partners is a leading wholesale distributor of motor fuels, convenience store operator, and owner and